600351 亚宝药业
2026/09 - 九个月2025/122024/122023/122022/12

盈利能力分析
净资产收益率 ROE (%)9.09811.0798.2706.7133.549
总资产报酬率 ROA (%)7.9449.3716.5614.9992.550
投入资产回报率 ROIC (%)8.82910.5137.5445.7892.926

边际利润分析
销售毛利率 (%)54.45952.51151.68157.85455.875
营业利润率 (%)19.54616.55511.1677.7784.545
息税前利润/营业总收入 (%)19.30516.57510.8457.6375.021
净利润/营业总收入 (%)15.43713.3888.3366.1833.848

收益指标分析
经营活动净收益/利润总额(%)100.57188.144100.817131.986142.178
价值变动净收益/利润总额(%)-5.37624.847-1.039-2.441-3.321
营业外收支净额/利润总额(%)-0.6860.966-2.686-3.3581.671

偿债能力分析
流动比率 (X)3.5004.0962.6792.2321.878
速动比率 (X)2.8533.2771.9691.6691.446
资产负债率 (%)15.01314.03118.31422.32527.219
带息债务/全部投入资本 (%)1.0522.2334.4088.60214.200
股东权益/带息债务 (%)9,290.0484,317.8492,119.6861,036.449588.042
股东权益/负债合计 (%)578.465625.501445.691345.935264.142
利息保障倍数 (X)-178.416-116.905-357.87068.94012.603

营运能力分析
应收账款周转天数 (天)31.79738.72542.16248.28256.801
存货周转天数 (天)107.280123.314118.605130.818145.597